About Seekyo

Seekyo is a biotechnology startup developing new-generation cancer treatments, known as ‘smart chemotherapy’ selective to tumors, reducing adverse effects from standard chemotherapy.
Thanks to its proprietary molecular platform, Seekyo develops a pipeline of drug candidates that can safely transport powerful anti-cancer agents throughout the body. Its lead compound, SKY01, is a Tumor MicroEnvironment (TME)-targeting smart chemotherapy, acting as an Antibody-Drug Conjugate (ADC). It can selectively target the microenvironment of solid tumors and release the active agent through enzyme activation.

This therapeutic strategy allows to spare healthy tissue, reduce adverse effects and consequently provide effective treatments that can improve patient’s quality of life.
Founded in 2018, Seekyo is an incubated startup located at Paris Biotech Santé, France.